REUTERS/Victoria Klesty/Illustration/File Photo Wegovy will soon be available to U.S. Medicare patients with heart conditions. The drug, the higher-dose version of semaglutide specifically for weight loss, costs around $1,300 a month. As well as treating obesity, in a major trial last summer the drug was shown to reduce heart attack and stroke risk in overweight patients. It’s not clear whether Wegovy reduces heart risk directly by making people slimmer — patients on the trial lost 9% of their body weight, on average — or by more direct means: In its lower-dose form, Ozempic, semaglutide is also a diabetes medication. Two in five Americans are obese, Gizmodo reported, making the U.S. a huge market for the drug. |